Nipah Virus at the Pandemic Threshold: The 2026 Outbreak in India

Nipah Virus (NiV) is one of the most deadly zoonotic pathogens known, with known case–fatality proportions fluctuating from 40% to 100%, recognized human-to-human transmission, and no certified vaccines or targeted therapeutics offered. Frequent outbreaks in India and Bangladesh, including transformed events stated in early 2026 (WHO DON593; preliminary figures are pending reconciliation), highlight the persistent threat posed by NiV to local and global health security. The NiV poses a significant risk of becoming a global pandemic due to several key characteristics: Humans are naturally susceptible to the virus. Multiple strains can transmit between people, though currently in a limited fashion. As an RNA virus, it has a very high mutation rate, increasing the potential for adaptation. If a human-adapted strain emerges in South Asia, the region’s high population density and extensive global travel connections could facilitate rapid and widespread transmission. This narrative review synthesizes recent outbreak patterns of NiV in India alongside current scientific findings and global research strategies to critically assess the present status of NiV diagnostics, treatments, and vaccine development. It highlights major scientific and operational challenges, including delayed outbreak detection, scarcity of point-of-care diagnostic tools, inadequate preparedness for conducting clinical trials during outbreaks, and the dependence on unconventional regulatory pathways for vaccine approval. The review places particular focus on the growing ecological and epidemiological factors driving spillover events, such as climate change, habitat disruption, changes in land use, and increased human–bat interactions, which together heighten the risk of recurrent spillover and sustained human-to-human transmission. This article offers revolutionary research and a framework grounded in a One Health approach, adding wildlife scrutiny, ecological monitoring, quick diagnostics, standardized animal and non-animal models, and outbreak-ready therapeutic and vaccine evaluation platforms. We discuss that supporting India’s role as a regional and global hub for NiV translational research, and countermeasure acceleration is critical to preventing NiV from surpassing the threshold from recurrent localized outbreaks to a global pandemic threat.